Webinar: The Value of Expanded Access Programs to Stakeholders and Best Practices for Successful Launch and Implementation

Chicago, IL, June 05, 2009 --(PR.com)-- Q1 Productions, a leading provider of educational programs for the pharmaceutical industry, will be hosting a webinar presented by representatives from PAREXEL.

About the Webinar
Pharmaceutical and biotechnology companies are faced with growing demand from physicians and patients for drugs that are not yet approved. To meet this demand, companies can use Expanded Access Programs to provide pre-approval access to their innovative medicines. Expanded Access Programs can bring significant value to the many stakeholders: sponsoring companies, physicians, and patients. This webinar will explore the value of these programs to stakeholders, and strategies for launching and operationalizing these programs.

About the Speakers
Lorna Laparan, Lorna Laparan, MPH, serves as a Portfolio Director, Peri Approval Clinical Excellence (PACE™), Americas in the Clinical Research Services business of PAREXEL International, a leading global biopharmaceutical services provider/ She oversees late-phase programs in North America for some of PAREXEL's large and key accounts. With over 18 years of experience in research and project management for large multi-centre studies, she has a proven track record in infrastructure development, initiation and execution of clinical trials, from conceptualization to analysis/reporting. One of her areas of specialty includes Expanded Access Programs after having directly managed or overseen some of the largest and complex EAPs for various oncology and HIV compounds.

Nayan Nanavati serves as Vice President, Peri Approval Clinical Excellence (PACE™), Americas in the Clinical Research Services business of PAREXEL International, a leading global biopharmaceutical services provider. Mr. Nanavati oversees a global team, which provides biopharmaceutical companies with a broad range of capabilities to support their product launch and marketing plans. He has in-depth expertise in late phase clinical development, including patient registries, safety studies, outcomes research, pharmacovigilance, pharmacoepidemiology, and expanded access programs. Mr. Nanavati is focused on providing clients with customized strategic and scientific solutions to move products from development to commercialization in a seamless and cost-effective manner.

PAREXEL is a proven and committed partner to drug developers and medical device manufacturers looking to bring innovative new products to market. Its Phase I-IV studies incorporate the full range of services from clinical study design to bioanalytics to peri-approval and post-marketing services, with an emphasis on First in Man and Proof of Concept studies. PAREXEL has decades of experience, deep expertise, and the global resources required to handle studies – and programs of studies – of any size, anywhere in the world.

The cost to register one participant for the webinar is $395. For unlimited participants the cost is $495.

To register visit: http://tinyurl.com/ow6p6f

When June 8, 2009, 2 pm EDT (90 minutes long)

Who Pharmaceutical and Biotechnology Executives

About the Organizer
Q1 Productions has over 25 years of combined event management experience, with previous roles in international Sales Management, Productions and Operations. Focusing on new or pending legislative issues, enhanced business processes or technologies that will drive efficiency and customer service, our conference programs provide solutions to the urgent needs of our attendees.

###